Pelabresib (CPI-0610) combined with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis: Durability of response and safety beyond week 24 Meeting Abstract
| Authors: | Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Gupta, V.; Palandri, F.; Devos, T.; Rampal, R. K.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; Kiladjian, J. J.; Verstovsek, S.; Mesa, R.; Colak, G.; Li, Q.; Klein, S.; Harrison, C. |
| Abstract Title: | Pelabresib (CPI-0610) combined with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis: Durability of response and safety beyond week 24 |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 586 |
| End Page: | 589 |
| Language: | English |
| ACCESSION: | WOS:000893223200238 |
| DOI: | 10.1182/blood-2022-158147 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
